stoxline Quote Chart Rank Option Currency Glossary
Xenon Pharmaceuticals Inc. (XENE)
36.14  -0.46 (-1.26%)    06-18 11:54
Open: 36.71
High: 36.71
Volume: 174,203
Pre. Close: 36.6
Low: 35.67
Market Cap: 2,727(M)
Technical analysis
2024-06-18 11:23:59 AM
Short term     
Mid term     
Targets 6-month :  46.55 1-year :  49.58
Resists First :  39.86 Second :  42.45
Pivot price 37.88
Supports First :  35.66 Second :  29.67
MAs MA(5) :  37.3 MA(20) :  38.07
MA(100) :  42.92 MA(250) :  39.68
MACD MACD :  -1 Signal :  -0.9
%K %D K(14,3) :  14.3 D(3) :  21.2
RSI RSI(14): 31
52-week High :  50.99 Low :  27.98
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ XENE ] has closed below the lower bollinger band by 8.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 37.42 - 37.73 37.73 - 37.93
Low: 35.61 - 35.95 35.95 - 36.17
Close: 36.16 - 36.68 36.68 - 37.03
Company Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Headline News

Mon, 17 Jun 2024
Oversold Conditions For Xenon Pharmaceuticals (XENE) - Nasdaq

Mon, 17 Jun 2024
Quarry LP Has $46000 Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World

Sun, 16 Jun 2024
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Perceptive Advisors LLC - MarketBeat

Fri, 14 Jun 2024
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update -

Thu, 13 Jun 2024
BVF Inc. IL Has $41 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World

Wed, 05 Jun 2024
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Financial Post

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 75 (M)
Shares Float 70 (M)
Held by Insiders 0.3 (%)
Held by Institutions 100.7 (%)
Shares Short 2,820 (K)
Shares Short P.Month 2,620 (K)
Stock Financials
EPS -2.73
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 11.76
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -17.1 %
Return on Equity (ttm) -24 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.92
Qtrly Earnings Growth 0 %
Operating Cash Flow -154 (M)
Levered Free Cash Flow -106 (M)
Stock Valuations
PE Ratio -13.34
PEG Ratio -1.5
Price to Book value 3.08
Price to Sales 0
Price to Cash Flow -17.77
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android